Role of Tivozanib in Renal Cell Carcinoma (RCC)

Thomas Hutson, DO, PharmD discusses the role of tivozanib in the treatment landscape for patients with renal cell carcinoma.

EP. 1: Treatment Options for Patients with Renal Cell Carcinoma (RCC)

June 15th 2022

An overview of the treatment options available for patients with renal cell carcinoma (RCC).

EP. 2: Clinical Implications of the TIVO-3 Trial

June 15th 2022

Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.

EP. 3: Tivozanib: Adverse Event Profile and How Toxicities are Managed

June 22nd 2022

Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.

EP. 4: Experience with Tivozanib in the 3rd Line Setting for Patients with RCC

June 22nd 2022

Dr Thomas Hutson shares his experience with tivozanib in his practice and ways to counsel patients regarding treatment options in the third-line setting.

EP. 5: Future Perspectives in Renal Cell Carcinoma (RCC)

June 29th 2022

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.